Trump to nominate CEA Chair Miran for Fed governor role
OXFORD, UK - Oxford Technology 2 VCT Plc announced its unaudited results for the quarter ending May 31, showing varied performance across its four share classes, according to a company press release.
The OT1 and OT2 share classes reported NAV increases of 3.1% and 4.1% respectively compared to February 28 figures. Meanwhile, OT3 saw a marginal decline of 0.3%, and OT4 experienced a more substantial decrease of 7.6%.
The quarterly valuation reflects changes in the company’s AIM-listed holdings, with Arecor Therapeutics (LON:AREC) plc declining by 6p to 42p per share, while Scancell Holdings Plc increased by 1.4p to 9.5p per share since February 28.
During the quarter, Oxford Technology 2 VCT invested £40,000 in ImmunoBiology Limited, with £30,000 allocated from the OT2 share class and £10,000 from the OT3 share class. The company also disposed of its holding in Mirriad Advertising (LON:MIRI) Plc from the OT4 share class, which was reported to have "negligible value."
No dividends were paid during the three-month period. The company’s total voting rights stand at 27,844,888 shares across all four share classes.
The unaudited NAV per share as of May 31, 2025, and total NAV returns including cumulative dividends for each share class are:
- OT1: 37.7p (92.7p total return)
- OT2: 15.8p (38.3p total return)
- OT3: 15.0p (57.0p total return)
- OT4: 18.3p (66.3p total return)
The directors stated that valuations of unquoted investments remain unchanged from February 28, 2025, except for adjustments related to the recent ImmunoBiology investment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.